UK MS Society calls on NICE to revise Tysabri assessment
The UK MS Society has expressed its grave concern over the National Institute for Clinical Excellence (NICE) evaluation report recommending that natalizumab (Tysabri) – a new therapy for people with rapidly evolving severe multiple sclerosis (MS) – should not be funded on the NHS.
